Understanding and eliminating inequalities and barriers that prevent optimal treatment of atrial fibrillation

22nd - 23rd January 2015

Venue
The European Heart House
2035 Route des Colles - Les Templiers
06903 Sophia Antipolis
France

Start
22nd January 2015
Thursday, 8:00 a.m.

End
23rd January 2015
Friday, 2:00 p.m.

Conference organization
The German Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA)

Scientific committee
Prof. Günter Breithardt, Münster, Germany
Prof. A. John Camm, London, UK
Prof. Paulus Kirchhof, Birmingham, UK / Münster, Germany
Prof. Gregory Y. H. Lip, Birmingham, UK

Contact address
Atrial Fibrillation Network (AFNET)
University Hospital Münster
Albert-Schweitzer-Campus 1 / Gebäude D11
Domagkstr. 11, 48149 Münster, Germany

Angelika Leute PhD
Phone +49 202 2623395
Mail afconsensus@af-net.eu

www.kompetenznetz-vorhofflimmern.de

Funded by Federal Ministry of Education and Research

The 5th joint consensus conference of the German Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA)
NEW DRUGS IN AF: REAL-LIFE QUESTIONS AND EXPERIENCES
10:10 NOACs in clinical practice: Updated answers from a professional organization | Hein Heidbüchel, Leuven, BE
10:30 Predicting and avoiding bleeding events in patients treated with non-vitamin K antagonist medications | Jonas Oldgren, Uppsala, SE
10:40 Patient preferences and patient-reported outcomes: A view from the ESC | Melanie Calvert, Birmingham, GB
10:50 Discussion

DRUGS AND INTERVENTIONS – THE FUTURE IS INTEGRATED!
11:10 10 minute “grab a coffee” break
11:20 Challenges on the main road – ensuring quality of AF ablation procedures | Gerd Hindricks, Leipzig, DE
11:30 Combination of antiarrhythmic drugs and catheter ablation | Harry Crijns, Maastricht, NL
11:40 Should we combine left atrial appendage occluders with oral anticoagulants in selected patients? | Thorsten Lewalter, Munich, DE
11:50 Discussion

NEW HEALTH MODIFIERS AND THERAPEUTIC TARGETS IN AF
13:00 Extracting biomarkers through bioinformatics | Monika Stoll, Münster, DE
13:10 Validation of biomarkers for AF: Incident AF, AF recurrence and AF related complications | Renate Schnabel, Hamburg, DE
13:20 ECG-based markers to guide rhythm control therapy | Ulrich Schotten, Maastricht, NL
13:30 Translating risk factors into disease mechanisms: Obesity | Stephane Hatem, Paris, FR
13:40 Adding a third dimension to genomic analysis and SNPs in AF | Patrick Ellinor, Boston, US
13:50 Making sense of genetic markers in AF – an update on pitx2 | Larissa Fabritz, Birmingham, GB
14:00 Discussion

Coffee break
14:30 LUNCH

AFNET
NEW DRUGS IN AF: REAL-LIFE QUESTIONS AND EXPERIENCES
10:10 NOACs in clinical practice: Updated answers from a professional organization | Hein Heidbüchel, Leuven, BE
10:30 Predicting and avoiding bleeding events in patients treated with non-vitamin K antagonist medications | Jonas Oldgren, Uppsala, SE
10:40 Patient preferences and patient-reported outcomes: A view from the ESC | Melanie Calvert, Birmingham, GB
10:50 Discussion
NEW Antiarrhythmic Drugs: Fit to Match Clinical Needs?
10:10 NOACs in Clinical Practice: Updated Answers from a Professional Organization
| Hein Heidbüchel, Leuven, BE
10:20 New Antiarrhythmic Drugs: Fit to Match Clinical Needs?
| John Camm, London, GB
10:30 Predicting and Avoiding Bleeding Events in Patients Treated with Non-Vitamin K Antagonist Medications
| Jonas Oldgren, Uppsala, SE
10:40 Patient Preferences and Patient-Reported Outcomes: A View from the ESC
| Melanie Calvert, Birmingham, GB
10:50 Discussion

CARDIOVASCULAR COMPLICATIONS IN ATRIAL FIBRILLATION
8:50 Finding atrial fibrillation – just keep looking, just keep looking... with new technologies! | Ben Freedman, Sydney, AU
9:00 The need to fully implement existing (proven) therapies in AF patients | Gregory Lip, Birmingham, GB
9:10 Pan-American perspective | Jonathan Piccini, Durham, US
9:20 Asia-Pacific perspective | Hung Fat Tse, Hong Kong, HK
9:30 The need for further improvement of atrial fibrillation management | Paulus Kirchhof, Birmingham, GB
9:40 Discussion
10:00 10 minute “grab a coffee” break
DRUGS AND INTERVENTIONS - THE FUTURE IS INTEGRATED!
11:20 Challenges on the main road – ensuring quality of AF ablation procedures | Gerd Hindricks, Leipzig, DE
11:30 Combination of antiarrhythmic drugs and catheter ablation | Harry Crijns, Maastricht, NL
11:40 Should we combine left atrial appendage occluders with oral anticoagulants in selected patients? | Thorsten Lewalter, Munich, DE
11:50 Discussion
12:10 LUNCH

NOVEL HEALTH MODIFIERS AND THERAPEUTIC TARGETS IN AF
13:00 Extracting biomarkers through bioinformatics | Monika Stoll, Münster, DE
13:10 Validation of biomarkers for AF: Incident AF, AF recurrence and AF related complications | Renate Schnabel, Hamburg, DE
13:20 ECG-based markers to guide rhythm control therapy | Ulrich Schotten, Maastricht, NL
13:30 Translating risk factors into disease mechanisms: Obesity | Stephane Hatem, Paris, FR
13:40 Adding a third dimension to genomic analysis and SNPs in AF | Patrick Ellinor, Boston, US
13:50 Making sense of genetic markers in AF – an update on pitx2 | Larissa Fabritz, Birmingham, GB
14:00 Discussion
14:30 Coffee Break
15:00 Break-out session 1 Workshops
15:15 Coffee Break
15:30 Report of break-out groups to plenary (10 min per group)
16:30 Adjourn, departure to dinner
Understanding and eliminating inequalities and barriers that prevent optimal treatment of atrial fibrillation

22nd - 23rd January 2015